PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded up 1.5% on Thursday . The stock traded as high as $1.80 and last traded at $1.66. 11,569 shares were traded during trading, an increase of 31% from the average session volume of 8,831 shares. The stock had previously closed at $1.63.
PharmaCyte Biotech Stock Performance
The company has a 50 day simple moving average of $1.69 and a two-hundred day simple moving average of $1.79.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
See Also
- Five stocks we like better than PharmaCyte Biotech
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
